Indian pharmaceutical company Zydus Lifesciences receives final US FDA approval for generic 7.5% Dapsone Gel, an acne treatment.
Zydus Lifesciences, an Indian pharmaceutical company, has received final US FDA approval to market its generic 7.5% Dapsone Gel, an acne treatment. The product, with annual US sales of $35.8m according to IQVIA MAT March 2024 data, will be manufactured at the company's topical facility in Ahmedabad, Gujarat. Zydus has previously received 395 approvals and filed over 460 ANDAs since FY 2003-04.
May 09, 2024
5 Articles